Ramon Arturo Franco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramon Arturo Franco has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Roberts Naunheim
Mass Eye and Ear Boston Massachusetts USA
10 shared publications Phillip C. Song
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
8 shared publications- Phillip C. Song
Harvard Medical School, Massachusetts Eye and Ear Infirmary
7 shared publications - Sungjin A. Song
Department of Otolaryngology Massachusetts Eye and Ear Boston Massachusetts USA
6 shared publications Inna Husain
Department of Otorhinolaryngology, Rush Medical College, Chicago, Illinois, U.S.A.
5 shared publicationsKanittha Choksawad
Department of Otolaryngology, Panyananthapikkhu Chonprathan Medical Center Srinakharinwirot University, Bangkok, Thailand
5 shared publications
Latest Publications
- 2 January 2026
- Published by Springer Nature
- p. 621-631
Techniques for Laryngotracheal Reconstruction
- 8 October 2025
- Published by Springer Nature
- p. 1-12
Techniques for Laryngotracheal Reconstruction
- 25 September 2024
- Published by Elsevier in Journal of Voice
- Vol. 40 (5) , 1501-1507
Complications and Revisions for Adduction Arytenopexy, Medialization Laryngoplasty, and Cricothyroid Subluxation over 19 Years
- 25 September 2024
- Published by Elsevier in Journal of Voice
- Vol. 40 (5) , 1501-1507
Complications and Revisions for Adduction Arytenopexy, Medialization Laryngoplasty, and Cricothyroid Subluxation over 19 Years
- 23 September 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (2) , 748-751
Instrumentation Considerations for Calcified Thyroid Cartilage during Chondrolaryngoplasty
Objective: Chondrolaryngoplasty, also known as thyroid cartilage reduction, alleviates gender dysphoria by reducing the thyroid cartilage to conform to a patient's gender identity. Reduction of the thyroid cartilage prominence (“Adam's apple”) is often performed with a scalpel, but in cases of cartilage calcification, rongeurs or drills are utilized. This study aims to characterize the success rate with scalpel‐only excision and relate this to patient age and operative time.Methods: Billing records were screened for chondrolaryngoplasties performed between 2020 and 2023 by a single surgeon. Patient demographics, operative notes, and operation duration were recorded. Type of instrumentation was categorized as scalpel only, rongeur, or drill. All cases began with attempted scalpel excision of cartilage and were transitioned to rongeur or drill if there was calcification that prevented sharp excision. Descriptive statistics were used to describe patient and surgical factors.Results: 52 individuals underwent chondrolaryngoplasty: 30 cases (57.7%) had soft cartilage requiring only a blade, 22 (42.3%) required use of either drill or rongeur. The average age of these groups was 25.7 (SE 1.8) and 41.3 years (SE 2.2), respectively; this difference was statistically significant (p < 0.0001). Cases requiring a drill or rongeur lasted on average 78.5 min (SE 2.3), whereas those using only a blade were shorter at 66.8 min (SE 2.7); this difference was significant (p = 0.0017).Conclusion: Cartilage calcification should be expected in a significant number of chondrolaryngoplasties, and surgeons should be prepared for this scenario. The need for alternative instrumentation is higher in older individuals and may extend procedural time.Level of Evidence: 4 Laryngoscope, 135:748–751, 2025
- 23 September 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (2) , 748-751
Instrumentation Considerations for Calcified Thyroid Cartilage during Chondrolaryngoplasty
Objective: Chondrolaryngoplasty, also known as thyroid cartilage reduction, alleviates gender dysphoria by reducing the thyroid cartilage to conform to a patient's gender identity. Reduction of the thyroid cartilage prominence (“Adam's apple”) is often performed with a scalpel, but in cases of cartilage calcification, rongeurs or drills are utilized. This study aims to characterize the success rate with scalpel‐only excision and relate this to patient age and operative time.Methods: Billing records were screened for chondrolaryngoplasties performed between 2020 and 2023 by a single surgeon. Patient demographics, operative notes, and operation duration were recorded. Type of instrumentation was categorized as scalpel only, rongeur, or drill. All cases began with attempted scalpel excision of cartilage and were transitioned to rongeur or drill if there was calcification that prevented sharp excision. Descriptive statistics were used to describe patient and surgical factors.Results: 52 individuals underwent chondrolaryngoplasty: 30 cases (57.7%) had soft cartilage requiring only a blade, 22 (42.3%) required use of either drill or rongeur. The average age of these groups was 25.7 (SE 1.8) and 41.3 years (SE 2.2), respectively; this difference was statistically significant (p < 0.0001). Cases requiring a drill or rongeur lasted on average 78.5 min (SE 2.3), whereas those using only a blade were shorter at 66.8 min (SE 2.7); this difference was significant (p = 0.0017).Conclusion: Cartilage calcification should be expected in a significant number of chondrolaryngoplasties, and surgeons should be prepared for this scenario. The need for alternative instrumentation is higher in older individuals and may extend procedural time.Level of Evidence: 4 Laryngoscope, 135:748–751, 2025
- 25 March 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (8) , 3713-3718
Increasing Prevalence of Voice Disorders in the USA: Updates in the COVID Era
Objective: To estimate the current prevalence of voice disorders among adults in the United States; to determine the association of individual factors with voice disorders.Methods: The 2022 National Health Interview Survey (NHIS) was analyzed to identify adults reporting voice problems in the past 12 months. Demographics were assessed, as well as the duration, severity, and resolution of the voice problem. The relationship between voice problems, gender, lost workdays, and long COVID was investigated. A comparison to the 2012 NHIS was made to determine changes in voice disorder prevalence.Results: 29.9 million Americans (95%CI[28.3–31.5]) annually report a voice problem, representing 12.2% of the population (95%CI[11.7–12.8%]). Overall, 26.8% and 13.2% reported the severity of their voice problem as moderate or severe, respectively. Only 5.1% (95%CI[4.3–6.0%]) of respondents sought treatment. Most voice problems were resolved within 1 week (53.0%,95%CI[50.9–55.1%]). Females were more likely than males to report a voice problem (14.4% vs. 10.0%,95%CI[13.7–15.1] and [9.3–10.7], respectively). The 17.6 million Americans with long COVID symptoms were more likely to have voice complaints than those without (21.1% vs. 11.6%,95%CI[18.9–23.5%] and [11.1–12.1%], respectively). Lost workdays were not significantly higher for those with voice disorders compared to those without (17.1 vs. 12.9 days,95%CI[12.0–22.1] and [11.0–14.8], respectively).Conclusions: Voice problems affect approximately 1 in 8 adults in the U.S. annually, demonstrating an alarming increased prevalence since 2012 using the same survey methodology. Relatively few individuals seek care for their voice problem, despite significant self‐reported impact. Further study is required regarding the impact of COVID and changes in voice use patterns on voice disorders.Level of Evidence: 3 Laryngoscope, 134:3713–3718, 2024
- 25 March 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (8) , 3713-3718
Increasing Prevalence of Voice Disorders in the USA: Updates in the COVID Era
Objective: To estimate the current prevalence of voice disorders among adults in the United States; to determine the association of individual factors with voice disorders.Methods: The 2022 National Health Interview Survey (NHIS) was analyzed to identify adults reporting voice problems in the past 12 months. Demographics were assessed, as well as the duration, severity, and resolution of the voice problem. The relationship between voice problems, gender, lost workdays, and long COVID was investigated. A comparison to the 2012 NHIS was made to determine changes in voice disorder prevalence.Results: 29.9 million Americans (95%CI[28.3–31.5]) annually report a voice problem, representing 12.2% of the population (95%CI[11.7–12.8%]). Overall, 26.8% and 13.2% reported the severity of their voice problem as moderate or severe, respectively. Only 5.1% (95%CI[4.3–6.0%]) of respondents sought treatment. Most voice problems were resolved within 1 week (53.0%,95%CI[50.9–55.1%]). Females were more likely than males to report a voice problem (14.4% vs. 10.0%,95%CI[13.7–15.1] and [9.3–10.7], respectively). The 17.6 million Americans with long COVID symptoms were more likely to have voice complaints than those without (21.1% vs. 11.6%,95%CI[18.9–23.5%] and [11.1–12.1%], respectively). Lost workdays were not significantly higher for those with voice disorders compared to those without (17.1 vs. 12.9 days,95%CI[12.0–22.1] and [11.0–14.8], respectively).Conclusions: Voice problems affect approximately 1 in 8 adults in the U.S. annually, demonstrating an alarming increased prevalence since 2012 using the same survey methodology. Relatively few individuals seek care for their voice problem, despite significant self‐reported impact. Further study is required regarding the impact of COVID and changes in voice use patterns on voice disorders.Level of Evidence: 3 Laryngoscope, 134:3713–3718, 2024
- Open Access
Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia
Head and neck squamous cell carcinoma (HNSCC) and its treatments are associated with substantial morbidity, often resulting in cosmetic deformity and loss of physiologic functions including speech and swallowing. Despite advancements in treatment, 5-year survival rates for mucosal malignancies remain below 70%. Effective prevention of HNSCC demands an understanding of the molecular pathways of carcinogenesis. Specifically, defining features of pre-cancerous dysplastic lesions that indicate a better or worse prognosis is necessary to help identify patients who are likely to develop a carcinoma and allow a more aggressive approach to management. There remains a need for identification of biomarkers that can provide both early prognostic and predictive value in clinical decision-making by serving as both therapeutic targets as well as predictors of therapy response. Here, we comprehensively review the most frequently altered molecular biomarkers of malignant transformation in head and neck dysplasia. These markers are involved in a wide range of cellular processes in head and neck carcinogenesis, including extracellular matrix degradation, cell motility and invasion, cell–cell adhesion, solute transport, immortalization, metabolism, the cell cycle and apoptosis, transcription, and cell signaling.
Open AccessMolecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia
Head and neck squamous cell carcinoma (HNSCC) and its treatments are associated with substantial morbidity, often resulting in cosmetic deformity and loss of physiologic functions including speech and swallowing. Despite advancements in treatment, 5-year survival rates for mucosal malignancies remain below 70%. Effective prevention of HNSCC demands an understanding of the molecular pathways of carcinogenesis. Specifically, defining features of pre-cancerous dysplastic lesions that indicate a better or worse prognosis is necessary to help identify patients who are likely to develop a carcinoma and allow a more aggressive approach to management. There remains a need for identification of biomarkers that can provide both early prognostic and predictive value in clinical decision-making by serving as both therapeutic targets as well as predictors of therapy response. Here, we comprehensively review the most frequently altered molecular biomarkers of malignant transformation in head and neck dysplasia. These markers are involved in a wide range of cellular processes in head and neck carcinogenesis, including extracellular matrix degradation, cell motility and invasion, cell–cell adhesion, solute transport, immortalization, metabolism, the cell cycle and apoptosis, transcription, and cell signaling.
- 3 November 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2285-2291
Predictive Outcomes of Deep Learning Measurement of the Anterior Glottic Angle in Bilateral Vocal Fold Immobility
Objective: (1) To compare maximum glottic opening angle (anterior glottic angle, AGA) in patients with bilateral vocal fold immobility (BVFI), unilateral vocal fold immobility (UVFI) and normal larynges (NL), and (2) to correlate maximum AGA with patient‐reported outcome measures.Methods: Patients wisth BVFI, UVFI, and NL were retrospectively studied. An open‐source deep learning‐based computer vision tool for vocal fold tracking was used to analyze videolaryngoscopy. Minimum and maximum AGA were calculated and correlated with three patient‐reported outcomes measures.Results: Two hundred and fourteen patients were included. Mean maximum AGA was 29.91° (14.40° SD), 42.59° (12.37° SD), and 57.08° (11.14° SD) in BVFI (N = 70), UVFI (N = 70), and NL (N = 72) groups, respectively (p < 0.001). Patients requiring operative airway intervention for BVFI had an average maximum AGA of 24.94° (10.66° SD), statistically different from those not requiring intervention (p = 0.0001). There was moderate negative correlation between Dyspnea Index scores and AGA (Spearman r = −0.345, p = 0.0003). Maximum AGA demonstrated high discriminatory ability for BVFI diagnosis (AUC 0.92, 95% CI 0.81–0.97, p < 0.001) and moderate ability to predict need for operative airway intervention (AUC 0.77, 95% CI 0.64–0.89, p < 0.001).Conclusions: A computer vision tool for quantitative assessment of the AGA from videolaryngoscopy demonstrated ability to discriminate between patients with BVFI, UVFI, and normal controls and predict need for operative airway intervention. This tool may be useful for assessment of other neurological laryngeal conditions and may help guide decision‐making in laryngeal surgery.Level of Evidence: III Laryngoscope, 133:2285–2291, 2023
- 3 November 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2285-2291
Predictive Outcomes of Deep Learning Measurement of the Anterior Glottic Angle in Bilateral Vocal Fold Immobility
Objective: (1) To compare maximum glottic opening angle (anterior glottic angle, AGA) in patients with bilateral vocal fold immobility (BVFI), unilateral vocal fold immobility (UVFI) and normal larynges (NL), and (2) to correlate maximum AGA with patient‐reported outcome measures.Methods: Patients wisth BVFI, UVFI, and NL were retrospectively studied. An open‐source deep learning‐based computer vision tool for vocal fold tracking was used to analyze videolaryngoscopy. Minimum and maximum AGA were calculated and correlated with three patient‐reported outcomes measures.Results: Two hundred and fourteen patients were included. Mean maximum AGA was 29.91° (14.40° SD), 42.59° (12.37° SD), and 57.08° (11.14° SD) in BVFI (N = 70), UVFI (N = 70), and NL (N = 72) groups, respectively (p < 0.001). Patients requiring operative airway intervention for BVFI had an average maximum AGA of 24.94° (10.66° SD), statistically different from those not requiring intervention (p = 0.0001). There was moderate negative correlation between Dyspnea Index scores and AGA (Spearman r = −0.345, p = 0.0003). Maximum AGA demonstrated high discriminatory ability for BVFI diagnosis (AUC 0.92, 95% CI 0.81–0.97, p < 0.001) and moderate ability to predict need for operative airway intervention (AUC 0.77, 95% CI 0.64–0.89, p < 0.001).Conclusions: A computer vision tool for quantitative assessment of the AGA from videolaryngoscopy demonstrated ability to discriminate between patients with BVFI, UVFI, and normal controls and predict need for operative airway intervention. This tool may be useful for assessment of other neurological laryngeal conditions and may help guide decision‐making in laryngeal surgery.Level of Evidence: III Laryngoscope, 133:2285–2291, 2023
- 1 November 2022
- Published by Elsevier in Journal of Voice
- Vol. 36 (6) , 853-858
The Poor Validity of Asymmetric Laryngoscopic Findings in Predicting Laterality in Vocal Fold Paresis
- 1 November 2022
- Published by Elsevier in Journal of Voice
- Vol. 36 (6) , 853-858
The Poor Validity of Asymmetric Laryngoscopic Findings in Predicting Laterality in Vocal Fold Paresis
- 18 October 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 47 (1) , 153-159
Long‐term outcomes of aminolevulinic acid photodynamic therapy for treatment of recalcitrant laryngeal premalignant lesions
Objective: To assess long‐term outcomes of ALA‐PDT in treating recalcitrant laryngeal leukoplakia.Study design: Retrospective Case‐Control.Methods: We reviewed all laryngeal leukoplakia patients treated with ALA‐PDT compared with angiolytic laser treatment alone (585 nm PDL or 532 nm KTP laser) from 2000 to 2019. Patients with laryngeal cancer (or a history of laryngeal cancer), leukoplakia previously treated with radiation and no pathologic report were excluded. Patient demographics, procedure details and outcomes were examined including histopathologic diagnosis, procedures performed, ALA usage, recurrence of leukoplakia and the development of cancer.Results: We identified 132 patients with laryngeal leukoplakia: 42 were treated with ALA‐PDT and 90 were treated with an angiolytic laser alone (Laser group). The proportion of cases of high‐grade dysplasia was 57.1% in the ALA‐PDT group compared to 32.2% in the Laser group. In high‐grade dysplasia cases, there was a statistically significant better recurrence‐free survival (RFS) at 12 months and 60 months in those who underwent ALA‐PDT 71.4% and 7.1% vs Laser 25% and 0% (p = .01). However, for overall groups, there was no difference in RFS (p = .25). Voice outcomes (patient subjective report) improved or were stable in 75% of subjects with no serious side effects reported.Conclusion: ALA‐PDT for recalcitrant and high‐grade dysplasia is highly effective with improved recurrence‐free survival compared to laser alone. ALA‐PDT may be an appropriate therapy in patients who have failed prior angiolytic laser alone.
- 18 October 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 47 (1) , 153-159
Long‐term outcomes of aminolevulinic acid photodynamic therapy for treatment of recalcitrant laryngeal premalignant lesions
Objective: To assess long‐term outcomes of ALA‐PDT in treating recalcitrant laryngeal leukoplakia.Study design: Retrospective Case‐Control.Methods: We reviewed all laryngeal leukoplakia patients treated with ALA‐PDT compared with angiolytic laser treatment alone (585 nm PDL or 532 nm KTP laser) from 2000 to 2019. Patients with laryngeal cancer (or a history of laryngeal cancer), leukoplakia previously treated with radiation and no pathologic report were excluded. Patient demographics, procedure details and outcomes were examined including histopathologic diagnosis, procedures performed, ALA usage, recurrence of leukoplakia and the development of cancer.Results: We identified 132 patients with laryngeal leukoplakia: 42 were treated with ALA‐PDT and 90 were treated with an angiolytic laser alone (Laser group). The proportion of cases of high‐grade dysplasia was 57.1% in the ALA‐PDT group compared to 32.2% in the Laser group. In high‐grade dysplasia cases, there was a statistically significant better recurrence‐free survival (RFS) at 12 months and 60 months in those who underwent ALA‐PDT 71.4% and 7.1% vs Laser 25% and 0% (p = .01). However, for overall groups, there was no difference in RFS (p = .25). Voice outcomes (patient subjective report) improved or were stable in 75% of subjects with no serious side effects reported.Conclusion: ALA‐PDT for recalcitrant and high‐grade dysplasia is highly effective with improved recurrence‐free survival compared to laser alone. ALA‐PDT may be an appropriate therapy in patients who have failed prior angiolytic laser alone.